19th Annual New York GU Cancers Congress®

Overview

In recent years, significant advancements in understanding the pathophysiology of genitourinary (GU) malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer, have driven a rapidly evolving therapeutic landscape. The optimal clinical management of patients with GU malignancies requires the integration of the latest data on both current and emerging therapies to enhance patient outcomes.

Now in its 19th year, the annual New York GU® meeting is dedicated to addressing knowledge and competence gaps arising from the abundance of new data. It focuses on selecting treatments based on patient and tumor characteristics and applying these findings in clinical practice to improve the care of patients with GU malignancies. The program promotes learning through three distinct educational modalities: expert presentations, panel discussions, and interactive tumor board-style case presentations. This unique format has proven highly effective in educating the multidisciplinary physician base on the comprehensive treatment and management of GU cancers.

Learning Objectives

Upon completion of this activity, learners will be better able to:

• Interpret advanced diagnostic and molecular testing strategies—including ctDNA and genomic profiling—for risk stratification and disease monitoring in GU malignancies
• Apply molecular and genomic test results to guide treatment selection and personalize care in patients with GU cancers
• Integrate emerging therapies with multidisciplinary strategies to optimize treatment sequencing and coordination across specialties
• Evaluate the toxicity profiles and management strategies for novel therapeutic agents used in GU malignancies, including targeted therapies, immunotherapies, and ADCs

Program Co-Chairs

Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD

To view full profile, click on the Program Co-Chairs tab above.

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 13.75 Contact Hours (Day 1=7.5; Day 2=6.25).

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Archive

Click below to view event overviews from previous years:

2025